Alaunos Therapeutics Files 8-K on Key Agreements
Ticker: TCRT · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
Alaunos Therapeutics filed an 8-K on June 9th, reporting material agreements and equity sales.
AI Summary
On June 9, 2025, Alaunos Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The company, formerly known as ZIOPHARM ONCOLOGY INC, is incorporated in Delaware and headquartered in Houston, TX.
Why It Matters
This filing indicates significant corporate actions, including definitive agreements and equity sales, which could impact the company's financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can carry inherent risks related to terms, dilution, and regulatory compliance.
Key Numbers
- 001-33038 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-1475642 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Registrant
- ZIOPHARM ONCOLOGY INC (company) — Former company name
- June 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Houston, TX (location) — Principal executive offices
FAQ
What specific material definitive agreement was entered into by Alaunos Therapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
What type of unregistered sales of equity securities occurred?
The filing mentions unregistered sales of equity securities, but the specific terms, amounts, and recipients are not detailed in the provided text.
What is the significance of the former company name ZIOPHARM ONCOLOGY INC?
ZIOPHARM ONCOLOGY INC was the former name of Alaunos Therapeutics, Inc., indicating a corporate name change.
Where are Alaunos Therapeutics' principal executive offices located?
Alaunos Therapeutics' principal executive offices are located at 2617 Bissonnet St Suite 225, Houston, TX 77005.
What is the filing date of this Current Report (8-K)?
The filing date of this Current Report (8-K) is June 10, 2025, with the earliest event reported on June 9, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).